Aliskiren Fumarate

U.S. net product sales of FILSPARI reached $103 million, representing 108% growth compared to prior year period; all-time high 908 new PSFs received during the quarter U.S. net product sales of FILSPARI totaled $322 million for full year 2025; total net product sales were $410 million for full year 2025 PDUFA target action date for FILSPARI in FSGS is April 13, 2026; Company positioned for a successful commercial launch, if approved Enrollment activities have resumed for the pivotal Phase 3 HARMONY Study of pegtibatinase in classical HCU SAN DIEGO--(BUSINESS WIRE)-- Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its fourth quarter and full year 2025 financial results and provided a corporate update. “2025 marked a year of meaningful advancement for Travere, strengthening both our commercial execution and long-term growth outlook,” said Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics. “In IgA nephropathy, continued adoption of FILSPARI underscores its foundational positioning and the positive impact we are delivering for patients and physicians. At the same time, we are extending our leadership across rare kidney and metabolic diseases by finalizing preparations for a potential launch in FSGS and progressing the Phase 3 HARMONY Study of pegtibatinase in classical HCU. Together, these efforts enhance our potential to reach more patients in the near term while reinforcing a trajectory for sustainable, long-term growth.” Financial Results for the Quarter and Year Ended December 31, 2025 U.S. net product sales for the fourth quarter of 2025 were $126.6 million, compared to $73.5 million for the same period in 2024. For the full year 2025, U.S. net product sales were $410.5 million, compared to $226.7 million for the same period in 2024. The increase is attributable to growth in sales of FILSPARI. Research and development (R&D) expenses for the fourth quarter of 2025 were $57.9 million, compared to $62.1 million for the same period in 2024. For the full year 2025, R&D expenses were $206.0 million, compared to $217.5 million for the same period in 2024. The decrease is largely attributable to lower costs associated with the development of pegtibatinase and decreased expense related to the development of FILSPARI as the PROTECT and DUPLEX trials advance to completion. On a non-GAAP adjusted basis, R&D expenses were $54.0 million for the fourth quarter and $189.3 million for the full year 2025, compared to $58.6 million and $203.3 million for the same periods in 2024. Selling, general, and administrative (SG&A) expenses for the fourth quarter of 2025 were $101.7 million, compared to $69.5 million for the same period in 2024. For the full year 2025, SG&A expenses were $337.2 million, compared to $264.1 million for the same period in 2024. The difference is largely attributable to investment in preparations for a potential FSGS launch in 2026, increased amortization expense related to capitalized FILSPARI royalties, and increased investment in the commercialization of FILSPARI in IgAN. On a non-GAAP adjusted basis, SG&A expenses were $76.0 million for the fourth quarter and $248.3 million for the full year 2025, compared to $51.6 million and $197.8 million for the same periods in 2024. Total other income, net for the fourth quarter of 2025 was $11.4 million, compared to $0.4 million for the same period in 2024. For the full year 2025, total other income, net was $13.6 million, compared to $3.3 million in the same period in 2024. Net income for the fourth quarter of 2025 was $2.7 million, or $0.03 per basic share, compared to a net loss of $60.3 million, or $0.73 per basic share for the same period in 2024. For the full year 2025, net loss was $25.5 million, or $0.29 per basic share, compared to $321.5 million, or $4.08 per basic share for the same period in 2024. On a non-GAAP adjusted basis, net income for the fourth quarter of 2025 was $33.3 million, or $0.37 per basic share, compared to a net loss of $39.0 million, or $0.47 per basic share for the same period in 2024. For the full year 2025, net income on a non-GAAP adjusted basis was $81.1 million, or $0.91 per basic share, compared to a net loss of $241.0 million, or $3.05 per basic shared for the same period in 2024. As of December 31, 2025, the Company had cash, cash equivalents, and marketable securities of $322.8 million. The Company expects to receive a $25 million sales-based milestone payment from Mirum Pharmaceuticals in the first half of 2026. Program Updates FILSPARI® (sparsentan) – IgA Nephropathy (IgAN) 908 new patient start forms (PSFs) were received during the fourth quarter, driven by continued demand from new and repeat prescribers. U.S. net product sales of FILSPARI totaled $103.3 million in the fourth quarter of 2025, representing 108% growth versus the fourth quarter of 2024; full year 2025 net product sales of FILSPARI totaled $322.0 million, representing 144% growth versus full year 2024. In 2026, the Company’s partner, Chugai Pharmaceutical, expects to submit a New Drug Application for sparsentan in Japan. Travere remains eligible to receive potential milestone payments related to the sparsentan regulatory process and net sales achievements in licensed territories, as well as tiered royalties. The Company’s partner, CSL Limited, has launched FILSPARI in Germany, Austria, Switzerland, Luxembourg, and the UK, and Travere remains eligible to receive additional market access and sales-based milestones. The SPARX Study evaluating FILSPARI in post-transplant patients with recurrent IgAN or FSGS is actively enrolling. In 2026, the Company expects to continue generating clinical evidence to support FILSPARI’s role as foundational therapy in IgAN, including through ongoing and planned studies and presentations at key medical meetings. FILSPARI® (sparsentan) – Focal Segmental Glomerulosclerosis (FSGS) The Company’s supplemental New Drug Application (sNDA) for FILSPARI in FSGS remains under review by the FDA with a Prescription Drug User Fee Act (PDUFA) target action date of April 13, 2026. The Company is well positioned for a successful commercial launch of FILSPARI in FSGS, if approved. Pegtibatinase (TVT-058) – Classical Homocystinuria (HCU) Pegtibatinase has the potential to become the first and only disease-modifying therapy for people living with HCU. The Company recently restarted enrollment activities in the pivotal Phase 3 HARMONY Study. The trial is expected to enroll approximately 70 patients aged 12 to 65 with a diagnosis of classical HCU and tHcy levels ≥50 µM while maintaining their standard-of-care treatment. Participants will be randomized 1:1 to receive 2.5 mg/kg of pegtibatinase or placebo, administered subcutaneously twice a week, for a 24-week blinded treatment duration. The primary endpoint is change from baseline in plasma tHcy levels, averaged across weeks 6 through 12, in patients receiving pegtibatinase compared with those receiving placebo. Conference Call Information Travere Therapeutics will host a conference call and webcast today, February 19, 2026, at 4:30 p.m. ET to discuss company updates as well as fourth quarter and full year 2025 financial results. To participate in the conference call, dial +1 (800) 549-8228 (U.S.) or +1 (646) 564-2877 (International), conference ID 86884 shortly before 4:30 p.m. ET. The webcast can be accessed on the Investor page of Travere’s website at ir.travere.com/events-presentations. Following the live webcast, an archived version of the call will be available for 30 days on the Company’s website. Use of Non-GAAP Financial Measures To supplement Travere’s financial results and guidance presented in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP adjusted financial measures in this press release and the accompanying tables. The Company believes that these non-GAAP financial measures are helpful in understanding its past financial performance and potential future results. They are not meant to be considered in isolation or as a substitute for comparable GAAP measures and should be read in conjunction with the consolidated financial statements prepared in accordance with GAAP. Travere’s management regularly uses these supplemental non-GAAP financial measures internally to understand, manage and evaluate its business and make operating decisions. In addition, Travere believes that the use of these non-GAAP measures enhances the ability of investors to compare its results from period to period and allows for greater transparency with respect to key financial metrics the Company uses in making operating decisions. Investors should note that these non-GAAP financial measures are not prepared under any comprehensive set of accounting rules or principles and do not reflect all of the amounts associated with the Company’s results of operations as determined in accordance with GAAP. Investors should also note that these non-GAAP financial measures have no standardized meaning prescribed by GAAP and, therefore, have limits in their usefulness to investors. In addition, from time to time in the future the Company may exclude other items, or cease to exclude items that it has historically excluded, for purposes of its non-GAAP financial measures; because of the non-standardized definitions, the non-GAAP financial measures as used by the Company in this press release and the accompanying tables may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by the Company’s competitors and other companies. As used in this press release, (i) the historical non-GAAP net income (loss) measures exclude from GAAP net income (loss), as applicable, stock-based compensation expense, amortization and depreciation expense, and income tax; (ii) the historical non-GAAP SG&A expense measures exclude from GAAP SG&A expenses, as applicable, stock-based compensation expense, and amortization and depreciation expense; (iii) the historical non-GAAP R&D expense measures exclude from GAAP R&D expenses, as applicable, stock-based compensation expense, and amortization and depreciation expense. About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com. FILSPARI® (sparsentan) U.S. Indication FILSPARI (sparsentan) is indicated to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression. IMPORTANT SAFETY INFORMATION BOXED WARNING: HEPATOTOXICITY AND EMBRYO-FETAL TOXICITY Because of the risk of hepatotoxicity, FILSPARI is available only through a restricted program called the FILSPARI REMS. Under the FILSPARI REMS, prescribers, patients and pharmacies must enroll in the program. Hepatotoxicity Some Endothelin Receptor Antagonists (ERAs) have caused elevations of aminotransferases, hepatotoxicity, and liver failure. In clinical studies, elevations in aminotransferases (ALT or AST) of at least 3-times the Upper Limit of Normal (ULN) have been observed in up to 3.5% of FILSPARI-treated patients, including cases confirmed with rechallenge. Measure transaminases and bilirubin before initiating treatment and then every 3 months during treatment. Interrupt treatment and closely monitor patients who develop aminotransferase elevations more than 3x ULN. FILSPARI should generally be avoided in patients with elevated aminotransferases (>3x ULN) at baseline because monitoring for hepatotoxicity may be more difficult and these patients may be at increased risk for serious hepatotoxicity. Embryo-Fetal Toxicity FILSPARI is contraindicated for use during pregnancy because it may cause fetal harm if used by pregnant patients. Therefore, in patients who can become pregnant, exclude pregnancy prior to initiation of FILSPARI. Advise use of effective contraception before the initiation of treatment, during treatment, and for two weeks after discontinuation of treatment with FILSPARI. When pregnancy is detected, discontinue FILSPARI as soon as possible. Contraindications FILSPARI is contraindicated in patients who are pregnant. Do not coadminister FILSPARI with angiotensin receptor blockers (ARBs), ERAs, or aliskiren. Warnings and Precautions Hepatotoxicity: Elevations in ALT or AST of at least 3-fold ULN have been observed in up to 3.5% of FILSPARI-treated patients, including cases confirmed with rechallenge. While no concurrent elevations in bilirubin >2-times ULN or cases of liver failure were observed in FILSPARI-treated patients in clinical trials, some ERAs have caused elevations of aminotransferases, hepatotoxicity, and liver failure. To reduce the risk of potential serious hepatotoxicity, measure serum aminotransferase levels and total bilirubin prior to initiation of treatment and then every 3 months during treatment. Advise patients with symptoms suggesting hepatotoxicity (nausea, vomiting, right upper quadrant pain, fatigue, anorexia, jaundice, dark urine, fever, or itching) to immediately stop treatment with FILSPARI and seek medical attention. If aminotransferase levels are abnormal at any time during treatment, interrupt FILSPARI and monitor as recommended. Consider re-initiation of FILSPARI only when hepatic enzyme levels and bilirubin return to pretreatment values and only in patients who have not experienced clinical symptoms of hepatotoxicity. Avoid initiation of FILSPARI in patients with elevated aminotransferases (>3x ULN) because monitoring hepatotoxicity in these patients may be more difficult and these patients may be at increased risk for serious hepatotoxicity. FILSPARI REMS: Due to the risk of hepatotoxicity, FILSPARI is available only through a restricted program called the FILSPARI REMS. Prescribers, patients, and pharmacies must be enrolled in the REMS program and comply with all requirements ( www.filsparirems.com). Embryo-Fetal Toxicity: Based on data from animal reproduction studies, FILSPARI may cause fetal harm when administered to a pregnant patient and is contraindicated during pregnancy. The available human data for ERAs do not establish the presence or absence of fetal harm related to the use of FILSPARI. Counsel patients who can become pregnant of the potential risk to a fetus. Exclude pregnancy before initiating treatment with FILSPARI. Advise patients who can become pregnant to use effective contraception prior to initiation of treatment, during treatment, and for two weeks after discontinuation of treatment with FILSPARI. When pregnancy is detected, discontinue FILSPARI as soon as possible. Hypotension: Hypotension has been observed in patients treated with ARBs and ERAs. There was a greater incidence of hypotension-associated adverse events, some serious, including dizziness, in patients treated with FILSPARI compared to irbesartan. In patients at risk for hypotension, consider eliminating or adjusting other antihypertensive medications and maintaining appropriate volume status. If hypotension develops, despite elimination or reduction of other antihypertensive medications, consider a dose reduction or dose interruption of FILSPARI. A transient hypotensive response is not a contraindication to further dosing of FILSPARI, which can be given once blood pressure has stabilized. Acute Kidney Injury: Monitor kidney function periodically. Drugs that inhibit the renin-angiotensin system (RAS) can cause kidney injury. Patients whose kidney function may depend in part on the activity of the RAS (e.g., patients with renal artery stenosis, chronic kidney disease, severe congestive heart failure, or volume depletion) may be at particular risk of developing acute kidney injury on FILSPARI. Consider withholding or discontinuing therapy in patients who develop a clinically significant decrease in kidney function while on FILSPARI. Hyperkalemia: Monitor serum potassium periodically and treat appropriately. Patients with advanced kidney disease, taking concomitant potassium-increasing drugs (e.g., potassium supplements, potassium-sparing diuretics), or using potassium-containing salt substitutes are at increased risk for developing hyperkalemia. Dosage reduction or discontinuation of FILSPARI may be required. Fluid Retention: Fluid retention may occur with ERAs, and has been observed in clinical studies with FILSPARI. FILSPARI has not been evaluated in patients with heart failure. If clinically significant fluid retention develops, evaluate the patient to determine the cause and the potential need to initiate or modify the dose of diuretic treatment then consider modifying the dose of FILSPARI. Most common adverse reactions The most common adverse reactions (≥5%) are hyperkalemia, hypotension (including orthostatic hypotension), peripheral edema, dizziness, anemia, and acute kidney injury. Drug interactions Renin-Angiotensin System (RAS) Inhibitors and ERAs: Do not coadminister FILSPARI with ARBs, ERAs, or aliskiren due to increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure). Strong and Moderate CYP3A Inhibitors: Avoid concomitant use of FILSPARI with strong CYP3A inhibitors. If a strong CYP3A inhibitor cannot be avoided, interrupt FILSPARI treatment. When resuming treatment with FILSPARI, consider dose titration. Monitor blood pressure, serum potassium, edema, and kidney function regularly when used concomitantly with moderate CYP3A inhibitors. Concomitant use with a strong CYP3A inhibitor increases sparsentan exposure which may increase the risk of FILSPARI adverse reactions. Strong CYP3A Inducers: Avoid concomitant use with a strong CYP3A inducer. Concomitant use with a strong CYP3A inducer decreases sparsentan exposure which may reduce FILSPARI efficacy. Antacids and Acid Reducing Agents: Administer FILSPARI 2 hours before or after administration of antacids. Avoid concomitant use of acid reducing agents (histamine H2 receptor antagonist and PPI proton pump inhibitor) with FILSPARI. Sparsentan exhibits pH-dependent solubility. Antacids or acid reducing agents may decrease sparsentan exposure which may reduce FILSPARI efficacy. Non-Steroidal Anti-Inflammatory Agents (NSAIDs), Including Selective Cyclooxygenase-2 (COX-2) Inhibitors: Monitor for signs of worsening renal function with concomitant use with NSAIDs (including selective COX-2 inhibitors). In patients with volume depletion (including those on diuretic therapy) or with impaired kidney function, concomitant use of NSAIDs (including selective COX-2 inhibitors) with drugs that antagonize the angiotensin II receptor may result in deterioration of kidney function, including possible kidney failure. CYP2B6, 2C9, and 2C19 Substrates: Monitor for efficacy of concurrently administered CYP2B6, 2C9, and 2C19 substrates and consider dosage adjustment in accordance with the Prescribing Information. Sparsentan decreases exposure of these substrates, which may reduce efficacy related to these substrates. P-gp and BCRP Substrates: Avoid concomitant use of sensitive substrates of P-gp and BCRP with FILSPARI. Sparsentan may increase exposure of these transporter substrates which may increase the risk of adverse reactions related to these substrates. Agents Increasing Serum Potassium: Monitor serum potassium frequently in patients treated with FILSPARI and other agents that increase serum potassium. Concomitant use of FILSPARI with potassium-sparing diuretics, potassium supplements, potassium-containing salt substitutes, or other drugs that raise serum potassium levels may result in hyperkalemia. Please see the full Prescribing Information, including BOXED WARNING, for additional Important Safety Information. Forward-Looking Statements This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, these statements are often identified by the words “on-track,” “positioned,” “look forward to,” “will,” “would,” “may,” “might,” “believes,” “anticipates,” “plans,” “expects,” “intends,” “potential,” or similar expressions. In addition, expressions of strategies, intentions or plans are also forward-looking statements. Such forward-looking statements include, but are not limited to, references to: continued progress with the FILSPARI launch in IgAN; statements regarding the Company’s expectations to continue generating clinical evidence to support FILSPARI’s role as foundational therapy in IgAN; statements and expectations regarding the potential to reach more patients in the near term; statements and expectations regarding the Company’s long-term growth outlook and trajectory; statements and expectations regarding the continued adoption and foundational positioning of FILSPARI in IgAN; statements and expectations regarding FDA’s review of the Company’s sNDA for FILSPARI in FSGS, and the expected timing and outcome thereof; statements regarding the Company’s positioning for a successful commercial launch in FSGS, if approved; statements and expectations regarding the Company’s pivotal Phase 3 HARMONY Study, including expectations regarding the timing and outcome thereof; statements regarding the potential for pegtibatinase to become the first and only disease-modifying therapy for people living with HCU; statements and expectations regarding the other clinical studies described herein; statements and expectations regarding potential milestone and royalty payments and the potential achievement and timing thereof; statements and expectations regarding the activities of the Company’s partners and collaborators; and statements regarding financial metrics and expectations related thereto. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties related to the Company’s sNDA for FILSPARI in FSGS, including the timing and outcome thereof. There is no guarantee that the FDA will grant approval of FILSPARI for FSGS on the anticipated timeline, or at all. The Company also faces risks and uncertainties related to its business and finances in general, the success of its commercial products, risks and uncertainties associated with its preclinical and clinical stage pipeline, risks and uncertainties associated with the regulatory review and approval process, risks and uncertainties associated with enrollment of clinical trials for rare diseases, and risks that ongoing or planned clinical trials may not succeed or may be delayed for safety, regulatory or other reasons. Specifically, the Company faces risks associated with the ongoing commercial launch of FILSPARI in IgAN, the timing and potential outcome of its and its partners’ clinical studies, market acceptance of its commercial products including efficacy, safety, price, reimbursement, and benefit over competing therapies, risks related to the challenges of manufacturing scale-up, risks associated with the successful development and execution of commercial strategies for such products, including FILSPARI, and risks and uncertainties related to the current administration, including but not limited to risks and uncertainties related to tariffs and the funding, staffing and prioritization of resources at government agencies including the FDA. The Company also faces the risk that it will be unable to raise additional funding that may be required to complete development of any or all of its product candidates, including as a result of macroeconomic conditions; risks relating to the Company’s dependence on contractors for clinical drug supply and commercial manufacturing; uncertainties relating to patent protection and exclusivity periods and intellectual property rights of third parties; risks associated with regulatory interactions; and risks and uncertainties relating to competitive products, including current and potential future generic competition with certain of the Company’s products, and technological changes that may limit demand for the Company’s products. The Company also faces additional risks associated with global and macroeconomic conditions, including health epidemics and pandemics, including risks related to potential disruptions to clinical trials, commercialization activity, supply chain, and manufacturing operations. You are cautioned not to place undue reliance on these forward-looking statements as there are important factors that could cause actual results to differ materially from those in forward-looking statements, many of which are beyond our control. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Investors are referred to the full discussion of risks and uncertainties, including under the heading “Risk Factors”, as included in the Company’s most recent Form 10-K, Form 10-Q and other filings with the Securities and Exchange Commission. TRAVERE THERAPEUTICS, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (in thousands, except share amounts) December 31, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 93,035 $ 58,535 Marketable debt securities, at fair value 229,761 312,166 Accounts receivable, net 80,134 27,116 Inventory 5,875 6,200 Prepaid expenses and other current assets 28,760 12,685 Total current assets 437,565 416,702 Long-term inventory 30,280 35,656 Property and equipment, net 4,022 5,336 Operating lease right-of-use assets 10,576 14,295 Intangible assets, net 113,868 103,974 Other assets 8,880 18,162 Total assets $ 605,191 $ 594,125 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 24,800 $ 23,534 Accrued expenses 126,035 86,028 Convertible debt, current portion — 68,678 Operating lease liabilities, current portion 5,875 5,405 Other current liabilities 3,194 17,106 Total current liabilities 159,904 200,751 Convertible debt, less current portion 311,724 310,310 Operating lease liabilities, less current portion 11,134 17,191 Other non-current liabilities 7,601 6,796 Total liabilities 490,363 535,048 Stockholders' Equity: Preferred stock $0.0001 par value; 20,000,000 shares authorized; no shares issued and outstanding as of December 31, 2025 and 2024 — — Common stock $0.0001 par value; 200,000,000 and 200,000,000 shares authorized; 90,922,868 and 87,452,835 issued and outstanding as of December 31, 2025 and 2024, respectively 9 9 Additional paid-in capital 1,588,721 1,506,315 Accumulated deficit (1,472,713 ) (1,447,167 ) Accumulated other comprehensive loss (1,189 ) (80 ) Total stockholders' equity 114,828 59,077 Total liabilities and stockholders' equity $ 605,191 $ 594,125 Note: Certain adjustments / reclassifications have been made to prior periods to conform to current year presentation. TRAVERE THERAPEUTICS, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except share and per share data) Three Months Ended December 31, Twelve Months Ended December 31, 2025 2024 2025 2024 (unaudited) Net product sales: FILSPARI $ 103,337 $ 49,644 $ 322,005 $ 132,222 Tiopronin products 23,271 23,902 88,455 94,485 Total net product sales 126,608 73,546 410,460 226,707 License and collaboration revenue 3,081 1,241 80,268 6,468 Total revenue 129,689 74,787 490,728 233,175 Operating expenses: Cost of goods sold 2,554 2,553 10,339 7,744 Research and development 57,869 62,067 206,011 217,496 Selling, general and administrative 101,694 69,501 337,202 264,119 In-process research and development — — — 65,205 Restructuring — 1,403 — 2,438 Total operating expenses 162,117 135,524 553,552 557,002 Operating loss (32,428 ) (60,737 ) (62,824 ) (323,827 ) Other income, net: Interest income 2,591 3,795 12,721 17,817 Interest expense (2,295 ) (2,817 ) (10,748 ) (11,182 ) Other income (expense), net 11,067 (581 ) 11,578 (3,318 ) Total other income, net 11,363 397 13,551 3,317 Loss from continuing operations before income tax provision (21,065 ) (60,340 ) (49,273 ) (320,510 ) Income tax (provision) benefit on continuing operations (921 ) 72 (988 ) (120 ) Loss from continuing operations, net of tax (21,986 ) (60,268 ) (50,261 ) (320,630 ) Income (loss) from discontinued operations, net of tax 24,715 4 24,715 (915 ) Net income (loss) $ 2,729 $ (60,264 ) $ (25,546 ) $ (321,545 ) Per share data Basic and diluted: Net income (loss) per common share $ 0.03 $ (0.73 ) $ (0.29 ) $ (4.08 ) Weighted average common shares outstanding 90,293,735 83,105,184 89,211,813 78,888,861 Note: Certain adjustments / reclassifications have been made to prior periods to conform to current year presentation. TRAVERE THERAPEUTICS, INC. AND SUBSIDIARIES RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION (in thousands, except share and per share data) (unaudited) Three Months Ended December 31, Twelve Months Ended December 31, 2025 2024 2025 2024 GAAP operating loss $ (32,428 ) $ (60,737 ) $ (62,824 ) $ (323,827 ) R&D operating expense (57,869 ) (62,067 ) (206,011 ) (217,496 ) Stock compensation 3,864 3,426 16,681 14,178 Non-GAAP R&D expense (54,005 ) (58,641 ) (189,330 ) (203,318 ) SG&A operating expense (101,694 ) (69,501 ) (337,202 ) (264,119 ) Stock compensation 7,600 5,789 28,187 22,735 Amortization & depreciation 18,137 12,093 60,743 43,555 Subtotal non-GAAP items 25,737 17,882 88,930 66,290 Non-GAAP SG&A expense (75,957 ) (51,619 ) (248,272 ) (197,829 ) Subtotal non-GAAP items 29,601 21,308 105,611 80,468 Non-GAAP operating (loss) income $ (2,827 ) $ (39,429 ) $ 42,787 $ (243,359 ) GAAP net income (loss) $ 2,729 $ (60,264 ) $ (25,546 ) $ (321,545 ) Non-GAAP operating adjustments 29,601 21,308 105,611 80,468 Income tax provision (benefit) 921 (72 ) 988 120 Non-GAAP net income (loss)(1) $ 33,251 $ (39,028 ) $ 81,053 $ (240,957 ) Per share data Basic and diluted: Non-GAAP net income (loss) per common share $ 0.37 $ (0.47 ) $ 0.91 $ (3.05 ) Weighted average common shares outstanding, basic 90,293,735 83,105,184 89,211,813 78,888,861 (1) Non-GAAP net loss includes income from discontinued operations but excludes non-GAAP adjustments for the effect of discontinued operations. Note: Certain adjustments / reclassifications have been made to prior periods to conform to current year presentation. Investors: 888-969-7879 ir@travere.com Media: 888-969-7879 mediarelations@travere.com

$信立泰(SZ002294)$引言：心血管疾病负担与治疗创新的时代呼唤心血管疾病是全球范围内导致死亡和残疾的首要原因，在中国，这一公共卫生挑战尤为严峻。根据《中国心血管健康与疾病报告2024》，心血管病目前仍位居中国城乡居民的首位死因，2021年分别占农村、城市死因的48.98%和47.35%，即每5例死亡中约2例归因于心血管病。高血压作为心血管疾病最重要的可干预危险因素，其防控形势同样不容乐观。中国高血压患者人数已超过2.45亿，但控制率仅16.8%，这意味着超过2亿高血压患者的血压未得到有效控制，长期暴露于心血管事件的高风险之中。与此同时，中国正经历着快速的人口老龄化进程。2024年，中国65岁及以上老年人口已达2.2亿人，占15.6%，已经进入“深度老龄化社会”。预计到2031年，65岁及以上老龄化率将首次达到20.2%，进入“超高龄社会”。老龄化与心血管疾病负担之间存在密切的正相关关系——随着年龄增长，高血压、冠心病、心力衰竭等心血管疾病的发病率显著上升。2019年60岁及60岁以上人群心脑血管病死亡占总死因的88.1%，这一数据凸显了老年人群心血管健康管理的紧迫性。在这一背景下，中国心血管药物研发迎来了历史性的突破时刻。2025年5月，国家药品监督管理局正式批准了深圳信立泰药业股份有限公司自主研发的1类新药——沙库巴曲阿利沙坦钙片（商品名：信超妥®）上市，用于治疗轻、中度原发性高血压。这是中国首款原研的血管紧张素受体脑啡肽酶抑制剂（ARNI）类药物，也是全球第二款获批的ARNI共晶药物。更令人期待的是，预计2027年，沙库巴曲阿利沙坦钙的心衰适应症也将完成III期临床并申报上市。届时，它将真正成为既能治“压”又能护“心”的全能型选手，为中国数亿心血管疾病患者带来全新的治疗选择。本文将从信超妥的研发创新、双重药理机制、临床疗效证据、安全性优势、在老龄化社会中的临床价值、市场前景预测以及对健康中国战略的意义等多个维度，全面解析这款中国原研创新药如何引领心血管治疗进入新时代。第一章信超妥的研发历程：中国心血管药物创新的里程碑1.1从跟跑到并跑：中国ARNI药物的自主创新之路血管紧张素受体脑啡肽酶抑制剂（ARNI）是近年来心血管治疗领域最具突破性的药物类别之一。2015年，诺华公司研发的沙库巴曲缬沙坦钠（商品名：诺欣妥）率先在美国获批用于治疗射血分数降低的慢性心力衰竭，开启了ARNI治疗时代。该药物上市后迅速成为心血管领域的明星产品，2024年全球销售额达78.22亿美元。在中国市场，诺欣妥也取得了显著成功，2024年国内公立医疗机构销售额增长至40.73亿元。然而，在信超妥问世之前，中国在ARNI领域长期处于“跟跑”状态，缺乏具有自主知识产权的创新产品。这一局面随着深圳信立泰药业股份有限公司的研发突破而彻底改变。信立泰自2014年前后开始布局创新药研发，尽管在2019年遭遇核心仿制药产品集采失利的挑战，公司仍坚定推进创新转型，加大研发投入。沙库巴曲阿利沙坦钙（研发代码：S086）作为信立泰重点研发项目之一，被列入国家“重大新药创制”科技重大专项，获得国家I类新药ARNI类抗心衰小分子S086的研发课题支持。研发团队历经上千次试验探索，克服了共晶药物研发中的诸多技术瓶颈，最终成功实现了产业化。2023年7月，中国国家药品监督管理局药品审评中心（CDE）公示信立泰1类新药沙库巴曲阿利沙坦钙片递交上市申请并获得受理。经过严格的审评流程，该药于2025年5月正式获得国家药监局批准上市。这一里程碑事件标志着中国在高端降压药物领域实现了从跟跑到并跑的重大转变。1.2共晶技术突破：在分子层面搭积木的创新智慧沙库巴曲阿利沙坦钙的核心技术突破在于其采用的药药共晶技术。药物共晶是指两种或以上活性药物成分在特定结晶条件下通过分子间作用力形成的稳定晶体结构，这种技术能够改善药物的溶解性、稳定性和生物利用度。然而，共晶药物的研发难度极大，被称为“在分子层面搭积木”，需要精确控制分子间的电荷分布和空间构象。全球范围内，成功的药药共晶产品寥寥无几。截至2025年6月30日，全球仅有三个药药共晶产品获批上市。沙库巴曲阿利沙坦钙作为全球第三个药药共晶药物，其研发成功体现了中国制药业在尖端技术领域的突破。通过创新的钙离子介导共晶技术，信超妥实现了两大突破：一是同步释放技术，使沙库巴曲与阿利沙坦的吸收半衰期差异缩小至0.8小时，血药浓度波动降低42%；二是长效控制优势，有效血药浓度维持时间延长至28小时，谷峰比值达78%（传统ARNi为62%）。这种共晶结构不仅提高了药物的稳定性和生物利用度，还带来了更优的药代动力学特性。与沙库巴曲缬沙坦钠相比，信超妥在同等日剂量下提供的沙库巴曲含量高出近20%。具体而言，信超妥240mg规格含有116mg沙库巴曲，而沙库巴曲缬沙坦钠200mg规格仅含有97mg沙库巴曲；信超妥480mg规格含有232mg沙库巴曲，而沙库巴曲缬沙坦钠400mg规格含有194mg沙库巴曲。这种更高的活性成分暴露效率为增强心血管保护效果奠定了物质基础。1.3专利保护与市场独占期：长期价值的保障创新药物的商业成功离不开有效的知识产权保护。沙库巴曲阿利沙坦钙拥有“血管紧张素II受体拮抗剂代谢产物与NEP抑制剂的复合物及其制备方法”等核心专利，化合物专利保护期至2037年。这意味着在专利到期前，信超妥将享有长达12年的市场独占期，为企业的研发投入回报和长期发展提供了有力保障。2025年12月，沙库巴曲阿利沙坦钙片（信超妥®）通过谈判新纳入《国家基本医疗保险、生育保险和工伤保险药品目录（2025年）》乙类范围。医保准入是创新药市场放量的关键一步，将显著提高药物的可及性和可负担性。参考同类药物谈判史（平均降价52%），预计信超妥的日治疗费用将控制在15-20元区间。这一价格水平使其在保持创新药价值的同时，能够惠及更广泛的患者群体。信立泰围绕沙库巴曲阿利沙坦钙登记了13项临床试验，其中包括3项III期临床试验。这种全面的临床开发策略不仅为药物上市提供了扎实的循证医学证据，也为后续适应症拓展和市场推广奠定了坚实基础。目前，沙库巴曲阿利沙坦钙片治疗慢性心衰适应症正处于III期临床研究阶段，该试验已于2022年6月入组首例受试者。随着心衰适应症的预期获批，信超妥的市场潜力将进一步释放。第二章双重药理机制：协同实现治压与护心的科学基础2.1高血压的病理生理学：双重失衡的治疗靶点要理解信超妥的治疗原理，首先需要了解高血压发生的病理生理机制。高血压并非单一因素导致的疾病，而是多种生理系统失衡的综合结果。其中，肾素-血管紧张素-醛固酮系统（RAAS）过度激活和利钠肽系统功能不足是导致血压升高的两个关键病理环节。RAAS系统是人体内重要的血压调节系统。当各种因素导致肾素分泌增加时，会启动一系列酶促反应，最终生成血管紧张素Ⅱ。血管紧张素Ⅱ通过作用于血管紧张素Ⅱ1型受体（AT1受体），引起血管收缩、促进醛固酮分泌导致水钠潴留、刺激心肌细胞肥大和纤维化，从而导致血压升高和靶器官损害。传统降压药物如血管紧张素转换酶抑制剂（ACEI，普利类）和血管紧张素Ⅱ受体拮抗剂（ARB，沙坦类）都是通过不同环节抑制RAAS系统发挥降压作用。与此同时，人体内还存在一个与RAAS系统作用相反的血压调节系统——利钠肽系统。利钠肽是心脏分泌的一种肽类激素，具有强大的排钠利尿、扩张血管、抑制交感神经活性、抗心肌肥厚和抗纤维化作用。然而，利钠肽在体内会被脑啡肽酶快速降解，半衰期很短。在高血压患者中，常常存在利钠肽系统功能相对不足的情况。理想的降压治疗应该同时针对这两个系统的失衡：一方面抑制过度活跃的RAAS系统，另一方面增强功能不足的利钠肽系统。这正是ARNI类药物设计的科学理念，也是信超妥能够实现“治压”与“护心”双重目标的药理基础。2.2沙库巴曲的作用机制：增强利钠肽系统的保护力量沙库巴曲是信超妥中的第一个活性成分，它是一种前体药物，口服后在体内代谢为活性产物LBQ657。LBQ657能够特异性抑制脑啡肽酶的活性，从而减少内源性利钠肽的降解。脑啡肽酶是一种广泛存在于体内的金属蛋白酶，主要负责降解多种肽类物质，包括利钠肽、缓激肽等。当脑啡肽酶被抑制后，利钠肽在体内的水平显著升高，其生理效应得到增强。具体而言，增强的利钠肽系统通过以下机制发挥降压和器官保护作用：第一，强大的排钠利尿作用。利钠肽能够促进肾脏排钠排水，减少血容量，从而降低血压。这一作用对于盐敏感性高血压患者尤为有益。第二，扩张血管降低外周阻力。利钠肽能够直接舒张血管平滑肌，同时通过抑制内皮素等缩血管物质的释放，间接扩张血管，降低外周血管阻力。第三，抑制交感神经活性。利钠肽能够抑制交感神经系统的过度激活，减少去甲肾上腺素的释放，从而降低心率和心肌收缩力，减轻心脏负荷。第四，抗心肌肥厚和抗纤维化。利钠肽能够抑制心肌细胞肥大和成纤维细胞增殖，减少胶原沉积，从而改善心室重构，保护心脏功能。第五，改善内皮功能。利钠肽能够促进一氧化氮的生成和释放，改善血管内皮功能，增强血管舒张能力。值得注意的是，单纯抑制脑啡肽酶虽然能够增强利钠肽系统，但也可能带来一些问题。脑啡肽酶同时负责降解缓激肽，当脑啡肽酶被抑制后，缓激肽水平可能升高，增加血管性水肿的风险。此外，利钠肽系统的增强可能反馈性激活RAAS系统，部分抵消其降压效果。这些潜在问题需要通过合理的药物组合来解决。2.3阿利沙坦的作用机制：强力阻断RAAS系统的升压通路阿利沙坦是信超妥中的第二个活性成分，它是我国自主研发的非磺酰脲类血管紧张素Ⅱ受体拮抗剂（ARB）。与沙库巴曲协同作用，阿利沙坦通过高选择性阻断AT1受体，有效对抗血管紧张素Ⅱ的升压和靶器官损害效应。阿利沙坦的药理特性具有多个显著优势。首先，它对AT1受体的抑制作用显著强于传统的ARB药物。研究显示，阿利沙坦对AT1受体的抑制作用是缬沙坦的4倍以上。这意味着在相同剂量下，阿利沙坦能够更有效地阻断血管紧张素Ⅱ的作用，产生更强的降压和靶器官保护效果。其次，阿利沙坦具有独特的药代动力学特性。它的血浆半衰期长达13.6小时，而缬沙坦的半衰期为9.9小时。更长的半衰期意味着更持久的药物作用，能够实现24小时平稳控压，有效覆盖夜间和清晨血压高峰，降低心血管事件风险。第三，阿利沙坦的代谢途径更为安全。它不依赖肝脏CYP450酶系代谢，而沙库巴曲缬沙坦钠中约20%的缬沙坦需经CYP450代谢。这一特性减少了药物相互作用的风险，特别适合合并使用他汀类、华法林等需经CYP450代谢药物的老年或慢病患者。对于肝功能不全患者，阿利沙坦也更为安全——轻中度肝功能不全无需调整剂量，而沙库巴曲缬沙坦钠在中度肝功能不全时需减量。第四，阿利沙坦对缓激肽B2受体具有独特的亲和力，能够作为B2受体的竞争性拮抗剂，减少血管性水肿的发生。这一特性与沙库巴曲的脑啡肽酶抑制作用形成了巧妙的平衡——沙库巴曲可能增加缓激肽水平，而阿利沙坦则通过拮抗B2受体减少其不良效应，从而降低血管性水肿的风险。2.4双重机制的协同效应：一加一大于二的治疗优势沙库巴曲与阿利沙坦的组合并非简单的药物叠加，而是基于深刻病理生理理解的协同设计。这两种成分通过以下机制实现协同增效：第一，作用机制的互补性。沙库巴曲通过增强利钠肽系统发挥降压和器官保护作用，而阿利沙坦通过阻断RAAS系统抑制升压通路。这两个系统在生理上相互拮抗，在病理状态下双重失衡，同时干预这两个系统能够更全面地纠正高血压的病理生理异常。第二，药代动力学的优化匹配。通过共晶技术，沙库巴曲与阿利沙坦实现了同步释放和协调吸收。两者的吸收半衰期差异缩小至0.8小时，血药浓度波动降低42%。这种协调的药代动力学特性确保了两种成分在体内能够同步发挥作用，避免因作用时间不匹配导致的疗效波动。第三，不良反应的相互制衡。如前所述，沙库巴曲可能通过增加缓激肽水平而增加血管性水肿风险，而阿利沙坦通过拮抗B2受体能够减少这一风险。这种相互制衡的设计使信超妥在增强疗效的同时，保持了良好的安全性特征。第四，靶器官保护的多重途径。沙库巴曲和阿利沙坦通过不同机制共同保护心脏、肾脏等靶器官。沙库巴曲主要通过利钠肽系统的抗肥厚、抗纤维化作用保护心脏；阿利沙坦主要通过阻断血管紧张素Ⅱ对AT1受体的作用，抑制心肌重构和肾小球硬化。双重保护机制使信超妥在降低血压的同时，能够更有效地预防和逆转靶器官损害。第五，血压节律的全面改善。信超妥不仅降低整体血压水平，还能特别改善夜间血压和清晨血压控制。阿利沙坦的长半衰期确保了对夜间血压的有效覆盖，而沙库巴曲的利钠利尿作用有助于减少夜间血容量负荷。这种对血压节律的全面改善对于降低心血管事件风险具有重要意义。这种双重协同机制使信超妥在降压效果、靶器官保护、血压平稳性等方面都表现出显著优势，为其在高血压和心力衰竭治疗中的应用奠定了坚实的科学基础。第三章临床疗效证据：从临床试验看信超妥的卓越表现3.1III期临床试验设计：专为中国人群量身打造的研究沙库巴曲阿利沙坦钙的临床开发遵循了高标准、严要求的原则，其关键性III期临床试验SAL086A301设计科学严谨，完全针对中国高血压人群的特点进行。这项研究采用了随机、双盲、阳性药平行对照、多中心的设计方案，共纳入1197例轻中度原发性高血压患者。所有研究中心均在中国，由中国的临床研究者主导，确保了研究结果对中国临床实践的高度适用性。试验设计的一个突出特点是包含了系统的剂量滴定方案。患者被随机分配接受沙库巴曲阿利沙坦钙240mg、480mg或阳性对照药奥美沙坦20mg治疗，治疗周期为12周。随后，研究还设置了长达40周的开放扩展期，所有受试者均接受沙库巴曲阿利沙坦钙治疗，最长随访时间达52周。这种长期观察设计为评估药物的持久疗效和长期安全性提供了宝贵数据。选择奥美沙坦作为阳性对照药具有重要的临床意义。奥美沙坦是临床上常用的ARB类药物，以其强效降压作用而闻名。将信超妥与奥美沙坦进行头对头比较，能够直接评估这种新型ARNI药物相对于传统强效ARB的疗效优势。研究的主要终点是治疗12周后平均诊室坐位收缩压（msSBP）的变化。次要终点包括24小时动态血压监测指标、血压达标率、血压节律改善情况以及安全性指标等。这种全面的终点设置能够多维度评估药物的临床价值。3.2强效降压效果：显著优于传统ARB的临床数据III期临床试验结果充分证实了信超妥卓越的降压效果。在为期12周的双盲治疗期内，信超妥240mg组平均诊室坐位收缩压下降25.07mmHg，480mg组下降28.22mmHg。这一降压幅度在高血压治疗药物中处于领先水平。与阳性对照药奥美沙坦20mg相比，信超妥显示出明确的疗效优势。研究结果显示，信超妥240mg组msSBP降幅非劣于奥美沙坦20mg组（组间差异：-1.9mmHg）；而信超妥480mg组msSBP降幅显著优于奥美沙坦20mg组（组间差异：-5.0mmHg，P<0.001）。这意味着在标准剂量下，信超妥的降压效果至少不劣于强效ARB奥美沙坦；而在高剂量下，其降压效果显著优于奥美沙坦。更令人印象深刻的是信超妥对24小时动态血压的全面改善。与奥美沙坦相比，信超妥两个剂量在24小时、日间及夜间血压降幅均更大（480mg组P≤0.001）。特别是对夜间血压的控制，信超妥表现出显著优势。夜间高血压是心血管事件的独立危险因素，中国超过76%的高血压患者存在夜间血压不达标的问题。信超妥能够有效降低夜间血压，填补了这一重要的治疗空白。信超妥还能改善血压节律，提高杓型血压比例。正常的血压节律表现为夜间血压较日间下降10%-20%（杓型节律），这种节律对心血管系统具有保护作用。许多高血压患者，特别是老年患者，常常出现夜间血压下降不足（非杓型）甚至夜间血压升高（反杓型）的异常节律。信超妥通过其独特的双重机制，能够有效纠正这些异常节律，恢复正常的血压昼夜模式。3.3剂量依赖性效应：灵活滴定满足个体化治疗需求信超妥的一个显著临床优势是其明确的剂量-效应关系。III期临床试验数据显示，从240mg增加到480mg，平均收缩压降幅进一步增加3.15mmHg（从25.07mmHg增加到28.22mmHg）。这种剂量依赖性的降压效果为临床提供了清晰的剂量调整路径。基于这一特性，信超妥成为中国首个、也是目前唯一拥有系统性剂量滴定设计III期研究支持的ARNI降压药。临床医生可以根据患者的血压控制情况，灵活调整药物剂量：初始治疗可从240mg开始，如果血压未达标，可逐步滴定至480mg。这种灵活的剂量方案特别适用于难治性高血压、老年高负荷患者等需要更强降压治疗的人群。在长达52周的观察期内，信超妥表现出持久的降压效果和良好的耐受性。开放扩展期的数据显示，延长治疗至52周时，血压控制依然稳定，长期安全性与耐受性良好。这对于需要终身治疗的高血压患者来说具有重要意义——长期有效的血压控制是预防心血管并发症的关键。信超妥的剂量灵活性还体现在其规格设计上。该药提供120mg和240mg两种规格，为不同体重的患者、肾功能不全患者以及需要与其他降压药联合使用的患者提供了更多选择。这种人性化的设计体现了以患者为中心的研发理念。3.4靶器官保护证据：超越降压的临床获益高血压治疗的最终目标不仅是降低血压数值，更重要的是预防和逆转靶器官损害，降低心血管事件风险。信超妥在这方面表现出显著优势，其靶器官保护作用通过多个机制实现。对心脏的保护是信超妥的核心优势之一。通过增强利钠肽系统和阻断RAAS系统的双重作用，信超妥能够有效改善心室重构。利钠肽具有强大的抗心肌肥厚和抗纤维化作用，而阿利沙坦能够抑制血管紧张素Ⅱ诱导的心肌细胞肥大和胶原沉积。这些机制共同作用，能够预防和逆转高血压引起的心脏结构改变。对肾脏的保护同样重要。高血压是慢性肾脏病的主要危险因素，而肾脏损害又会进一步加重高血压，形成恶性循环。信超妥通过多种途径保护肾功能：一方面，其强效降压作用直接降低肾小球内压力；另一方面，阿利沙坦能够特异性扩张出球小动脉，进一步降低肾小球滤过压；此外，利钠肽系统的增强还能抑制肾小球系膜细胞增殖和细胞外基质沉积。对血管的保护也不容忽视。高血压会导致血管内皮功能损伤、动脉硬化加速。信超妥通过改善内皮功能、抑制血管炎症反应、减少氧化应激等多重机制保护血管健康。特别是对夜间血压的有效控制，能够减少血管壁的持续高压负荷，延缓动脉硬化的进展。虽然信超妥的心衰适应症尚在III期临床研究中，但其药理机制和已有的高血压临床数据都强烈提示其对心力衰竭的潜在治疗价值。沙库巴曲缬沙坦钠（诺欣妥）在心力衰竭治疗中取得的成功为ARNI类药物在这一领域的应用提供了有力佐证。预计2027年信超妥心衰适应症获批后，将为心力衰竭患者提供新的治疗选择。3.5特殊人群疗效：老年患者与共病患者的治疗优势在老龄化社会中，老年高血压患者和伴有多种共病的患者构成了高血压人群的主体。信超妥在这些特殊人群中表现出独特的治疗优势。老年高血压患者常伴有动脉硬化、血压节律紊乱、多药合用等问题，对血压波动极为敏感。信超妥凭借阿利沙坦的超长半衰期（13.6小时），能够实现24小时平稳控压，有效覆盖夜间血压反跳和清晨高血压，减少血压波动对老年患者的影响。III期临床试验的亚组分析显示，老年患者（≥65岁）使用信超妥无需调整剂量，临床研究证实安全有效。对于伴有慢性肾脏病（CKD）的高血压患者，信超妥也显示出良好的应用前景。研究显示，轻中度肾功能不全（eGFR30–90mL/min/1.73m²）患者使用信超妥无需调整剂量，但需定期监测肾功能。与传统ARB相比，信超妥在CKD患者中可能具有更好的肾脏保护作用，这一优势需要进一步的临床研究证实。糖尿病合并高血压是临床常见的共病状态，这类患者的心血管风险显著增高。信超妥对这类患者具有多重益处：一方面，其强效降压作用有助于降低糖尿病患者的血管并发症风险；另一方面，研究显示沙库巴曲阿利沙坦钙能够降低血清尿酸水平，这对于常伴有高尿酸血症的糖尿病患者尤为有益。盐敏感性高血压在中国人群中较为常见，特别是在老年患者中。信超妥通过增强利钠肽系统的排钠利尿作用，特别适合盐敏感性高血压的治疗。这种针对性的作用机制使其在中国高血压人群中具有独特的治疗价值。伴有左室肥厚的高血压患者是心血管事件的高危人群。信超妥通过其抗心肌肥厚和抗纤维化的双重机制，能够有效逆转左室肥厚，改善心脏结构和功能。这一作用对于预防心力衰竭的发生和发展具有重要意义。第四章安全性优势：在强效降压中的安全保障4.1总体安全性特征：大规模临床试验的验证结果药物的安全性是临床广泛应用的基础，特别是对于需要长期甚至终身服用的降压药物。信超妥在安全性方面表现出色，这在其III期临床试验中得到了充分验证。在纳入1197例轻中度原发性高血压患者的III期确证性试验（SAL086A301）中，信超妥展现了良好的安全性和耐受性。为期12周的双盲治疗期内，信超妥240mg、480mg与奥美沙坦的不良反应发生率相似，且无剂量相关性。信超妥发生率≥1.0%的不良反应主要为直立性低血压和头晕，这些也是降压药物常见的不良反应。更为重要的是长期安全性数据。在为期40周的开放滴定治疗期内，所有受试者均接受信超妥治疗，总发生率≥1.0%的不良反应为：高脂血症、低钾血症、高甘油三酯血症、血葡萄糖升高、直立性低血压、尿路感染。接受信超妥治疗的受试者在开放滴定治疗期内报告的不良反应与双盲治疗期相似。特别值得关注的是，在长达52周的观察期内，信超妥治疗组未发生任何一例血管性水肿，无高钾血症报告（仅1例短暂血钾升高），无肾功能损害事件（肌酐/肾小球滤过率异常均常见）。这一安全性特征在ARNI类药物中表现突出。与沙库巴曲缬沙坦钠相比，信超妥在安全性方面显示出优势。根据MAIC（匹配调整间接比较）的锚定研究，沙库巴曲阿利沙坦钙在不良事件的发生率显著低于沙库巴曲缬沙坦钠，包括高脂血症的发生率、高尿酸血症的发生率、血糖升高的发生率。这些数据表明信超妥在保持强效降压的同时，具有更优的安全性特征。4.2血管性水肿风险：显著降低的临床优势血管性水肿是ARNI类药物需要特别关注的安全性问题。沙库巴曲缬沙坦钠在大型PARADIGM-HF研究中，血管性水肿发生率约为0.5%~0.7%，在黑人人群中这一比例可达2.4%。血管性水肿虽然罕见，但可能危及生命，特别是喉头水肿需要紧急医疗干预。信超妥在血管性水肿风险控制方面表现出显著优势。在纳入超过1153例中国患者的临床研究中，信超妥治疗组未发生任何一例血管性水肿。这一优异的安全性表现可能归因于多个因素：首先，阿利沙坦对缓激肽B2受体具有独特的亲和力，能够作为B2受体的竞争性拮抗剂，减少血管性水肿的发生。当沙库巴曲抑制脑啡肽酶可能导致缓激肽水平升高时，阿利沙坦的这一特性能够有效对抗其不良效应。其次，信超妥采用的共晶技术可能优化了药物的释放特性，使两种成分的释放更加协调，减少了药代动力学波动可能带来的安全性风险。第三，信超妥的临床研究完全在中国人群中进行，而中国人群本身血管性水肿的发生率可能低于其他种族人群。但即便如此，零血管性水肿的发生率仍然是一个令人印象深刻的安全性成就。这一安全性优势对于临床实践具有重要意义。血管性水肿的担忧常常影响医生对ARNI类药物的处方决策，特别是对于有ACEI/ARB相关血管性水肿病史的患者。信超妥的低血管性水肿风险使其在这些患者中可能具有更好的应用前景，当然，对于有明确血管性水肿病史的患者，仍应谨慎使用。4.3电解质与代谢影响：对血钾和尿酸的双重益处高血压患者常伴有电解质紊乱和代谢异常，这些并发症既可能是高血压的结果，也可能因降压治疗而加重。信超妥在电解质和代谢影响方面表现出有益的特性。对血钾的影响是评估降压药物安全性的重要指标。传统RAAS抑制剂（ACEI和ARB）可能引起高钾血症，特别是在肾功能不全患者中。令人鼓舞的是，在信超妥的III期临床试验中，无高钾血症报告，仅1例出现短暂血钾升高。这一安全性特征可能与其独特的药物组合有关——沙库巴曲增强利钠肽系统促进排钠，可能有助于维持钾平衡。对尿酸代谢的影响是信超妥的另一个亮点。研究显示，沙库巴曲阿利沙坦钙能够降低血清尿酸水平。这一特性对于高血压患者具有多重临床意义：第一，高尿酸血症是高血压的常见共病，两者常相互促进，增加心血管风险。信超妥的降尿酸作用有助于打破这一恶性循环。第二，许多高血压患者需要使用利尿剂治疗，而利尿剂常引起尿酸升高。信超妥的降尿酸作用可能部分抵消利尿剂的这一不良影响。第三，对于合并痛风的高血压患者，信超妥可能提供双重获益——既控制血压，又降低尿酸水平，减少痛风发作。对血糖和血脂的影响也值得关注。与传统ARNI相比，信超妥在高脂血症、高甘油三酯血症、血糖升高方面的发生率较低。这对于常伴有代谢综合征的高血压患者来说是一个有利特性。这些代谢益处使信超妥特别适合伴有多种代谢异常的高血压患者，这类患者在临床实践中十分常见，特别是在老年人群中。4.4肝肾功能影响：特殊人群的安全使用考量肝肾功能不全是高血压患者常见的合并症，也是影响降压药物选择的重要因素。信超妥在肝肾功能不全患者中显示出良好的安全性特征。对于肝功能不全患者，信超妥具有明显优势。阿利沙坦不依赖肝脏CYP450酶系代谢，而沙库巴曲缬沙坦钠中约20%的缬沙坦需经CYP450代谢。这一特性使信超妥在肝功能不全患者中更为安全。临床建议指出，轻中度肝功能不全患者使用信超妥无需调整剂量，而沙库巴曲缬沙坦钠在中度肝功能不全时需减量。重度肝功能损害、胆汁性肝硬化和胆汁淤积患者禁用信超妥。对于肾功能不全患者，信超妥也表现出良好的耐受性。轻中度肾功能不全（eGFR30–90mL/min/1.73m²）患者使用信超妥无需调整剂量，但需定期监测肾功能。与传统ARB相比，信超妥在CKD患者中可能具有更好的肾脏保护作用，但这一优势需要更多的临床研究证实。值得注意的是，在糖尿病或肾功能损害（eGFR<60mL/min/1.73m²）患者中，禁止将信超妥与阿利吉仑联合使用。这一禁忌是基于两类药物联合可能显著增加高钾血症和肾功能损害的风险。对于老年患者，信超妥同样安全适用。临床研究证实，老年患者（≥65岁）使用信超妥无需调整剂量。这一特性对于老龄化社会中的高血压管理具有重要意义，因为老年患者常常需要多种药物联合治疗，药物相互作用的风险较高。4.5药物相互作用：简化治疗的优势高血压患者，特别是老年患者和共病患者，常常需要同时使用多种药物。药物相互作用是临床实践中需要重点关注的问题。信超妥在药物相互作用方面具有优势。阿利沙坦不依赖肝脏CYP450酶系代谢的特性显著减少了与经CYP450代谢药物的相互作用风险。这对于需要同时使用他汀类降脂药、华法林抗凝药、某些抗心律失常药等经CYP450代谢药物的患者来说是一个重要优势。然而，信超妥有一个重要的药物相互作用禁忌需要特别注意：绝对禁止与ACEI（普利类）药物联合使用。基于其他ARNI药物的使用经验，沙库巴曲与ACEI联用可升高缓激肽水平，显著增加血管性水肿风险。换药规则为：停用ACEI后，至少等待36小时方可启用信超妥；停用信超妥后，也需间隔36小时才能开始ACEI治疗。信超妥与某些利尿剂联合使用时需要谨慎监测电解质。虽然信超妥本身对血钾影响较小，但与保钾利尿剂（如螺内酯、氨苯蝶啶）或补钾剂联合使用时，仍需定期监测血钾水平。对于需要联合使用其他降压药物的患者，信超妥与钙通道阻滞剂（CCB）或β受体阻滞剂的联合通常是安全的，且可能产生协同降压效果。临床数据显示，信超妥240mg联合氨氯地平5mg可使收缩压额外降低12-15mmHg。总体而言，信超妥的药物相互作用风险较低，这使其特别适合需要多药治疗的复杂患者。但临床医生仍需了解其与ACEI的绝对禁忌，并注意与其他药物的合理搭配。第五章在老龄化社会中的临床价值：应对多重挑战的解决方案5.1老年高血压的特点与治疗挑战中国正快速步入深度老龄化社会，老年高血压患者构成了高血压人群的主体。根据流行病学数据，中国高血压患者中有超过70%为65岁以上老年人。老年高血压具有一系列独特的临床特点，这些特点对治疗提出了特殊挑战。老年高血压常表现为单纯收缩期高血压，即收缩压升高而舒张压正常甚至偏低。这种血压模式反映了老年患者动脉硬化的程度，治疗时需要特别注意避免舒张压过度降低。血压变异性增大是老年高血压的另一特点。老年患者的血压更容易受到体位、进食、情绪等因素的影响，表现为较大的血压波动。这种血压不稳定性增加了治疗难度，也增加了心血管事件的风险。异常血压节律在老年患者中更为常见。许多老年高血压患者表现为非杓型甚至反杓型血压节律，即夜间血压下降不足或反而升高。这种异常节律与靶器官损害和心血管事件风险密切相关。多重用药问题在老年高血压患者中十分突出。老年患者常伴有多种慢性疾病，需要同时使用多种药物，这增加了药物相互作用的风险，也影响了患者的治疗依从性。器官储备功能下降使老年患者对血压波动的耐受性降低。老年患者常伴有不同程度的心、脑、肾等靶器官损害，这些器官对血压波动的调节能力下降，更容易受到血压异常的影响。这些特点使得老年高血压的治疗需要更加个体化、更加谨慎。理想的降压药物应该能够平稳降压、改善血压节律、减少血压波动、具有良好的安全性和耐受性、药物相互作用风险低。信超妥在这些方面表现出显著优势，使其成为老年高血压治疗的优选药物。5.2信超妥在老年高血压中的治疗优势针对老年高血压的特点和治疗挑战，信超妥展现出多方面的治疗优势，使其特别适合老年患者使用。长效平稳降压是信超妥的核心优势之一。阿利沙坦的半衰期长达13.6小时，能够实现24小时平稳控压，有效覆盖夜间血压。这对于血压变异性大的老年患者尤为重要，可以减少血压波动，提高治疗安全性。改善血压节律是信超妥的另一突出优势。临床研究显示，信超妥能够提高杓型血压比例，纠正异常的血压昼夜模式。这对于常伴有非杓型或反杓型血压节律的老年患者具有重要临床意义，有助于降低心血管事件风险。良好的安全性和耐受性使信超妥适合老年患者长期使用。III期临床试验证实，老年患者（≥65岁）使用信超妥无需调整剂量，安全有效。特别是其低血管性水肿风险、对血钾影响小等安全性特征，减少了老年患者治疗中的担忧。药物相互作用风险低是信超妥在老年多药治疗中的优势。阿利沙坦不依赖CYP450代谢的特性减少了与常用药物的相互作用。这对于需要同时使用多种药物的老年患者来说是一个重要考量。靶器官保护作用使信超妥在老年高血压治疗中具有长期获益。老年患者常伴有不同程度的心、脑、肾等靶器官损害，信超妥通过多重机制保护这些器官，可能延缓疾病进展，改善长期预后。剂量灵活性为老年高血压的个体化治疗提供了便利。信超妥明确的剂量-效应关系和可滴定特性，使临床医生可以根据老年患者的具体情况调整治疗方案。特别是对于难治性高血压的老年患者，剂量增加至480mg可能提供更强的降压效果。这些优势使信超妥在老年高血压治疗中具有独特的临床价值。随着中国人口老龄化的加速，能够满足老年高血压特殊治疗需求的药物将越来越重要。5.3共病管理：高血压合并其他慢性病的综合治疗在老龄化社会中，高血压很少单独存在，常与其他慢性疾病共存，形成复杂的共病状态。心血管-肾脏-代谢（CKM）综合征作为连接心血管、肾脏与代谢异常的重要临床综合征，其综合管理是当前医学界关注的焦点。信超妥在共病管理中表现出多重优势。高血压合并糖尿病是临床最常见的共病组合之一。这类患者的心血管风险显著增高，需要强效降压和多重器官保护。信超妥不仅提供强效降压，还能改善血糖代谢，降低心血管事件风险。其肾脏保护作用对于预防糖尿病肾病也具有重要意义。高血压合并慢性肾脏病（CKD）是另一常见共病。这类患者的治疗需要平衡降压效果与肾脏保护，避免肾功能进一步恶化。信超妥在CKD患者中显示出良好的安全性和潜在的肾脏保护作用。与传统ARB相比，其双重机制可能提供更全面的肾脏保护。高血压合并心力衰竭是心血管疾病发展的终末阶段。虽然信超妥的心衰适应症尚在III期临床研究中，但其药理机制强烈提示对心力衰竭的治疗价值。预计2027年心衰适应症获批后，信超妥将为这类患者提供新的治疗选择。高血压合并高尿酸血症/痛风在中国人群中十分常见。信超妥的降尿酸作用为这类患者提供了双重获益——既控制血压，又降低尿酸水平，减少痛风发作。这一特性在临床实践中具有重要价值。高血压合并肥胖/代谢综合征的治疗需要综合考虑血压、血糖、血脂等多重因素。信超妥对代谢指标的有利影响使其特别适合这类患者。与传统降压药物相比，它可能提供更全面的代谢益处。对于伴有多种共病的老年患者，治疗简化是提高依从性的关键。信超妥每日一次的给药方案和良好的耐受性，有助于减少患者的用药负担，提高长期治疗依从性。信超妥在共病管理中的这些优势，使其成为复杂高血压患者治疗的优选药物。随着中国人口老龄化和慢性病负担的加重，能够综合管理多种共病的药物将具有越来越重要的临床价值。5.4难治性高血压的治疗突破难治性高血压是指在生活方式改善的基础上，使用包括利尿剂在内的三种或以上不同作用机制的降压药物（通常包括一种利尿剂）足量治疗后，血压仍不能达标的情况。在老年高血压患者中，难治性高血压的比例较高，治疗挑战大。信超妥为难治性高血压的治疗提供了新的突破。其双重作用机制针对高血压的多个病理环节，可能克服传统单机制药物的局限性。临床研究显示，信超妥480mg剂量能够提供更强的降压效果，特别适合难治性高血压患者。对于已经使用多种降压药物但血压仍不达标的患者，信超妥可以作为强化治疗的选择。其与钙通道阻滞剂（CCB）的联合使用可能产生协同降压效果。临床数据显示，信超妥240mg联合氨氯地平5mg可使收缩压额外降低12-15mmHg。信超妥对夜间血压的有效控制对于难治性高血压患者尤为重要。许多难治性高血压患者存在夜间血压升高的问题，这是血压难以控制的重要原因之一。信超妥通过其长效作用，能够有效降低夜间血压，提高整体血压达标率。对于伴有慢性肾脏病的难治性高血压患者，信超妥可能提供更好的肾脏保护。传统降压药物在这类患者中常常效果有限，且可能加重肾功能损害。信超妥的双重保护机制可能为这类患者提供更优的治疗选择。难治性高血压患者常需要多药联合治疗，药物相互作用和不良反应是治疗中的主要顾虑。信超妥良好的安全性和低相互作用风险，使其适合在多药方案中使用。随着信超妥在临床中的广泛应用，预计将为更多难治性高血压患者提供有效的治疗选择。这对于改善高血压控制率、降低心血管事件风险具有重要意义。5.5预防心力衰竭：从高血压到心衰的全程管理高血压是心力衰竭最重要的危险因素之一。长期未控制的高血压会导致左心室肥厚、心脏舒张功能受损，最终发展为心力衰竭。在老龄化社会中，高血压相关心力衰竭的负担日益加重。信超妥在预防心力衰竭方面具有独特价值。其双重机制不仅强效降压，还能直接保护心脏结构，预防和逆转心室重构。这对于阻断高血压向心力衰竭的发展路径具有重要意义。对于已经出现左心室肥厚的高血压患者，信超妥可能提供更有效的心脏保护。左心室肥厚是心力衰竭的独立预测因素，逆转左心室肥厚可以降低心力衰竭风险。信超妥通过其抗心肌肥厚和抗纤维化的双重作用，可能更有效地逆转左心室肥厚。改善心脏舒张功能是信超妥的另一潜在优势。许多高血压患者，特别是老年患者，常伴有心脏舒张功能不全，这是心力衰竭的早期表现。信超妥可能通过改善心肌顺应性、降低心脏负荷等机制，改善心脏舒张功能。对于心力衰竭前期（心衰B期）患者，即已有心脏结构改变但尚无心力衰竭症状的患者，信超妥可能提供早期干预的机会。这类患者是预防心力衰竭的关键人群，早期有效干预可以延缓或防止心力衰竭的发生。预计2027年信超妥心衰适应症获批后，将为高血压合并心力衰竭或心力衰竭高风险患者提供全程管理方案。从高血压治疗到心力衰竭预防和治疗，信超妥可能提供连续性的心血管保护。在老龄化社会中，预防心力衰竭比治疗已发生的心力衰竭具有更大的公共卫生意义。信超妥在这方面的潜在价值，使其在心血管疾病全程管理中占据重要地位。第六章市场前景与规模预测：老龄化时代的巨大潜力6.1中国高血压治疗市场现状要理解信超妥的市场前景，首先需要了解中国高血压治疗市场的现状。这是一个规模巨大但仍有巨大发展空间的市场。根据最新数据，中国高血压患者人数已超过2.45亿，约占成年人口的四分之一。然而，高血压的控制率仅为16.8%，这意味着超过2亿高血压患者的血压未得到有效控制。这一控制率远低于发达国家，也低于《健康中国行动（2019-2030年）》设定的目标。高血压治疗药物市场已经形成了相当的规模。2021年，中国高血压药物市场规模达1035亿元。这一市场主要由几类药物主导：钙通道阻滞剂（CCB，如氨氯地平、硝苯地平）、血管紧张素转换酶抑制剂（ACEI，普利类）、血管紧张素Ⅱ受体拮抗剂（ARB，沙坦类）、利尿剂和β受体阻滞剂。近年来，随着国家药品集中采购（集采）政策的推进，许多经典降压药的价格大幅下降。截至2025年，已有6款ARB药物纳入国家集采目录，包括厄贝沙坦、奥美沙坦等，价格降幅达70%-90%。这一方面降低了患者的治疗负担，另一方面也为创新药留出了市场空间。创新降压药物的市场渗透率仍然较低。近年来国内获批的抗高血压新药不多，仅有日本武田的美阿沙坦钾片、默克的比索洛尔氨氯地平片和诺华的沙库巴曲缬沙坦等5.1类新药获批进口。国内高血压化药销售榜单仍由氨氯地平、左氨氯地平、硝苯地平等经典降压药主导。随着诊断标准的更新，高血压治疗市场还有进一步扩大的潜力。2023年《中国高血压临床实践指南》将成人高血压诊断界值下调至130/80mmHg，潜在适用人群扩大12.9%。这意味着更多人群需要降压治疗，市场容量将进一步增加。总体而言，中国高血压治疗市场正经历结构性变革。随着集采政策的深入推进，传统降压药价格大幅下降，为创新药留出了市场空间。截至2025年，已有6款ARB药物纳入国家集采目录，价格降幅达70%-90%。这一方面降低了患者的治疗负担，另一方面也为像信超妥这样的创新药物创造了差异化竞争的机会。创新降压药物的市场渗透率仍然较低。近年来国内获批的抗高血压新药不多，仅有日本武田的美阿沙坦钾片、默克的比索洛尔氨氯地平片和诺华的沙库巴曲缬沙坦等5.1类新药获批进口。国内高血压化药销售榜单仍由氨氯地平、左氨氯地平、硝苯地平等经典降压药主导。随着诊断标准的更新，高血压治疗市场还有进一步扩大的潜力。2023年《中国高血压临床实践指南》将成人高血压诊断界值下调至130/80mmHg，潜在适用人群扩大12.9%。这意味着更多人群需要降压治疗，市场容量将进一步增加。总体而言，中国高血压治疗市场呈现出“存量巨大、增量可期、结构优化”的特点。在这个超过千亿规模的市场中，创新药物正迎来历史性发展机遇。6.2信超妥的市场定位与竞争优势在竞争激烈的高血压治疗市场中，信超妥凭借其独特的双重机制和差异化优势，确立了明确的市场定位。首先，信超妥定位于高端降压药物市场。与传统降压药物相比，信超妥不仅提供强效降压，更重要的是提供全面的靶器官保护。这一价值定位使其能够避开集采带来的价格竞争，专注于价值医疗。其次，信超妥针对特定患者群体进行精准定位。特别适合以下人群：1）难治性高血压患者；2）伴有左心室肥厚的高血压患者；3）夜间血压控制不佳的患者；4）合并慢性肾脏病的高血压患者；5）老年高血压患者。这些患者群体对治疗效果有更高要求，也愿意为更好的治疗效果支付溢价。第三，信超妥与信立泰现有产品形成战略协同。信立泰已上市的阿利沙坦酯片（信立坦）、阿利沙坦酯氨氯地平片（复立坦）等产品覆盖了轻中度高血压患者。信超妥的加入使公司产品线更加完整，能够覆盖从轻中度到难治性高血压的全谱患者。信超妥的竞争优势主要体现在以下几个方面：机制创新优势：作为全球第二款ARNI类药物，信超妥的双重机制在降压效果和靶器官保护方面具有明显优势。临床研究显示，其480mg剂量组降压效果显著优于强效ARB奥美沙坦。安全性优势：零血管性水肿发生率、对血钾影响小、不依赖CYP450代谢等安全性特征，使其在临床应用中具有更好的耐受性和更低的药物相互作用风险。本土化优势：作为中国原研创新药，信超妥更了解中国患者的疾病特点和治疗需求。其临床研究完全在中国人群中开展，数据更贴近中国临床实践。成本优势：与进口同类药物相比，信超妥在保持创新药价值的同时，可能具有更好的成本效益。特别是在医保谈判后，其价格将更加亲民，惠及更多患者。专利保护优势：化合物专利保护期至2037年，为长期市场独占提供了保障。这些优势使信超妥在高血压治疗市场中具有强大的竞争力，有望在高端降压药物领域占据重要地位。6.3市场规模预测：从高血压到心衰的双重驱动信超妥的市场规模增长将受到高血压和心力衰竭两个适应症的双重驱动。根据华创证券的分析，在高血压和心衰适应症均获批后，信超妥的销售峰值有望达到47亿元人民币。高血压适应症市场：中国高血压患者超过2.45亿人，但控制率仅16.8%。这意味着有超过2亿高血压患者的血压未得到有效控制。信超妥凭借其强效降压和靶器官保护优势，有望在难治性高血压、高危高血压等细分市场获得显著份额。假设信超妥在高血压患者中的渗透率达到1%，按2.45亿患者基数计算，覆盖患者数可达245万人。按日均治疗费用20元计算，年市场规模可达178.85亿元。考虑到实际渗透率可能逐步提升，以及不同患者群体的支付能力差异，信超妥在高血压适应症的销售峰值预计可达16.5亿元。心力衰竭适应症市场：中国心力衰竭患者约1300万人。诺欣妥（沙库巴曲缬沙坦钠）2024年国内公立医疗机构销售额达40.73亿元。作为同类药物，信超妥凭借其机制优势和本土化特点，有望在心力衰竭治疗市场获得重要份额。假设信超妥在心衰患者中的渗透率达到10%，按1300万患者基数计算，覆盖患者数可达130万人。按日均治疗费用30元计算，年市场规模可达142.35亿元。考虑到心衰患者的治疗依从性通常高于高血压患者，以及信超妥可能具有的价格优势，其在心衰适应症的销售峰值预计可达30.5亿元。两个适应症叠加后，信超妥的总销售峰值预计可达47亿元。这一预测基于以下假设：1）高血压适应症2025年获批上市；2）心衰适应症2027年获批上市；3）医保准入顺利推进；4）市场推广有效开展；5）竞争格局相对稳定。值得注意的是，信超妥的市场表现还将受到以下因素影响：1）与诺欣妥的竞争态势；2）其他ARNI类药物的研发进展；3）高血压治疗指南的更新；4）医保支付政策的调整；5）患者支付能力的变化。6.4竞争格局分析：与诺欣妥的直接竞争信超妥上市后，将与诺华的诺欣妥（沙库巴曲缬沙坦钠）展开直接竞争。诺欣妥作为全球首款ARNI类药物，在中国市场已经建立了强大的品牌影响力和市场份额。诺欣妥的市场表现：诺欣妥2017年7月在中国获批HFrEF适应症，2019年纳入医保目录，2021年6月获批高血压适应症。药智数据显示，2023年诺欣妥国内公立医疗机构销售额约28.1亿元，同比增长63.66%，2024年进一步增长至40.73亿元。有分析预测2027年诺欣妥销售额将突破47亿元。信超妥的竞争策略：面对诺欣妥的竞争，信超妥需要采取差异化竞争策略：机制差异化：虽然同为ARNI类药物，但信超妥采用沙库巴曲与阿利沙坦的共晶结构，在药代动力学、安全性等方面具有独特优势。特别是零血管性水肿发生率、不依赖CYP450代谢等特性，可以作为重要的差异化卖点。临床证据差异化：信超妥的临床研究完全在中国人群中开展，数据更贴近中国临床实践。特别是对夜间血压的改善、对老年患者的安全性等证据，可以针对中国患者的特殊需求进行精准推广。价格差异化：作为国产原研药，信超妥在成本控制方面可能具有优势。通过医保谈判获得合理价格后，可以提供更好的成本效益，吸引价格敏感的患者和医疗机构。渠道差异化：信立泰在中国市场拥有成熟的销售网络和渠道资源。通过自营、招商互补的多渠道模式，可以强化市场覆盖，特别是在基层医疗市场的渗透。服务差异化：信立泰正在探索数字化慢病管理模式，通过建立院内外一体化的高血压筛、诊、治、管数字闭环，提升患者依从性和血压达标率。这种增值服务可以增强患者粘性，提高品牌忠诚度。竞争态势预测：在短期内，诺欣妥凭借先发优势和品牌积累，可能仍将保持市场领先地位。但随着信超妥市场推广的深入，特别是在心衰适应症获批后，两者之间的竞争将更加激烈。长期来看，信超妥有望凭借其差异化优势，在特定细分市场获得竞争优势，甚至可能在某些领域实现超越。6.5老龄化社会的市场机遇中国正快速步入深度老龄化社会，这为心血管疾病治疗药物带来了巨大的市场机遇。2024年，中国65岁及以上老年人口为2.2亿人，占15.6%，已经进入“深度老龄化社会”。预计到2031年，65岁及以上老龄化率将首次达到20.2%，进入“超高龄社会”。老龄化与心血管疾病负担：老龄化是心血管疾病负担增长的最主要原因。2019年60岁及60岁以上人群心脑血管病死亡占总死因的88.1%。随着年龄增长，高血压、冠心病、心力衰竭等心血管疾病的发病率显著上升。老年高血压的特点：老年高血压常表现为单纯收缩期高血压、血压变异性增大、异常血压节律等特点。这些特点对治疗提出了特殊要求，需要更加平稳、长效、安全的降压药物。信超妥在老年患者中的优势：信超妥特别适合老年高血压患者，其优势体现在：1）长效平稳降压，阿利沙坦半衰期长达13.6小时；2）改善血压节律，提高杓型血压比例；3）良好的安全性和耐受性；4）药物相互作用风险低；5）靶器官保护作用。市场规模预测：随着老龄化进程的加速，老年高血压患者数量将持续增长。预计到2030年，中国65岁及以上老年人口将超过3亿人。假设老年高血压患病率为60%，则老年高血压患者数量将达1.8亿人。结语：治压护心，引领健康新时代沙库巴曲阿利沙坦钙片（信超妥）的研发成功和临床应用，标志着中国心血管药物创新进入了新阶段。这款中国原研的ARNI类药物，凭借其独特的双重机制、卓越的临床疗效和良好的安全性，为高血压和心力衰竭患者提供了全新的治疗选择。信超妥的核心价值在于“治压”与“护心”的完美结合。通过同时增强利钠肽系统和阻断RAAS系统，它不仅强效降低血压，更重要的是保护心脏、肾脏等靶器官，预防和逆转心血管损害。这种全面的保护作用，特别适合老年患者、高危患者和难治性高血压患者。在老龄化社会背景下，信超妥具有重要的临床意义和社会价值。随着中国人口老龄化的加速，心血管疾病负担日益加重。信超妥通过提供更安全、更有效的治疗方案，有助于改善老年人群的生活质量，减轻家庭和社会的照护负担，支持健康中国战略的实施。展望未来，信超妥的市场前景广阔。预计在高血压和心衰适应症均获批后，其销售峰值可达47亿元。随着研发管线的拓展、国际化战略的推进和数字化慢病管理的探索，信立泰正从传统制药企业向创新药平台转型，为中国制药行业的发展探索新路径。信超妥的成功启示我们，创新是医药行业发展的根本动力。只有坚持自主创新、注重临床价值、构建产品生态、拥抱数字变革，中国制药企业才能在激烈的国际竞争中脱颖而出，为人类健康事业作出更大贡献。